Prudential Financial Inc. lowered its holdings in Zoetis Inc. (NYSE:ZTS) by 11.4% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,132,243 shares of the company’s stock after selling 274,320 shares during the quarter. Prudential Financial Inc. owned 0.44% of Zoetis worth $135,952,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of the business. Ironwood Investment Management LLC grew its stake in Zoetis by 0.7% during the second quarter. Ironwood Investment Management LLC now owns 6,870 shares of the company’s stock worth $429,000 after buying an additional 48 shares during the last quarter. Benjamin F. Edwards & Company Inc. grew its stake in Zoetis by 1.3% during the second quarter. Benjamin F. Edwards & Company Inc. now owns 4,201 shares of the company’s stock worth $262,000 after buying an additional 55 shares during the last quarter. Wilbanks Smith & Thomas Asset Management LLC grew its stake in Zoetis by 1.8% during the second quarter. Wilbanks Smith & Thomas Asset Management LLC now owns 5,682 shares of the company’s stock worth $354,000 after buying an additional 98 shares during the last quarter. First Manhattan Co. grew its stake in Zoetis by 1.1% during the second quarter. First Manhattan Co. now owns 9,099 shares of the company’s stock worth $567,000 after buying an additional 99 shares during the last quarter. Finally, Gilder Gagnon Howe & Co. LLC grew its stake in Zoetis by 1.3% during the second quarter. Gilder Gagnon Howe & Co. LLC now owns 7,795 shares of the company’s stock worth $486,000 after buying an additional 100 shares during the last quarter. 92.90% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Zoetis Inc. (NYSE:ZTS) traded up $1.02 during midday trading on Tuesday, reaching $69.71. 3,884,094 shares of the company traded hands, compared to its average volume of 2,410,000. Zoetis Inc. has a fifty-two week low of $48.24 and a fifty-two week high of $70.48. The firm has a market capitalization of $33,580.00, a price-to-earnings ratio of 31.51, a P/E/G ratio of 2.02 and a beta of 1.02. The company has a debt-to-equity ratio of 2.45, a current ratio of 2.80 and a quick ratio of 1.95.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, November 2nd. The company reported $0.65 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.63 by $0.02. Zoetis had a net margin of 18.29% and a return on equity of 62.39%. The business had revenue of $1.35 billion for the quarter, compared to analyst estimates of $1.32 billion. During the same period in the prior year, the business posted $0.52 earnings per share. Zoetis’s revenue was up 8.5% compared to the same quarter last year. equities research analysts anticipate that Zoetis Inc. will post 2.35 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 1st. Investors of record on Thursday, November 9th will be issued a $0.105 dividend. The ex-dividend date is Wednesday, November 8th. This represents a $0.42 annualized dividend and a yield of 0.60%. Zoetis’s dividend payout ratio is currently 22.11%.

Several analysts have weighed in on the stock. Zacks Investment Research raised shares of Zoetis from a “hold” rating to a “buy” rating and set a $71.00 price objective on the stock in a research note on Thursday, October 12th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $75.00 price objective on shares of Zoetis in a research note on Wednesday, September 6th. BidaskClub cut shares of Zoetis from a “hold” rating to a “sell” rating in a research note on Friday, October 6th. Morgan Stanley upped their price objective on shares of Zoetis from $61.00 to $70.00 and gave the stock an “equal weight” rating in a research note on Friday. Finally, Goldman Sachs Group, Inc. (The) reaffirmed a “neutral” rating and set a $62.00 price objective on shares of Zoetis in a research note on Monday, August 7th. Two research analysts have rated the stock with a sell rating, five have given a hold rating and eleven have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $67.06.

COPYRIGHT VIOLATION WARNING: “Prudential Financial Inc. Has $135.95 Million Position in Zoetis Inc. (ZTS)” was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this article on another domain, it was stolen and reposted in violation of international copyright & trademark law. The legal version of this article can be accessed at https://www.thecerbatgem.com/2017/11/07/prudential-financial-inc-has-135-95-million-position-in-zoetis-inc-zts.html.

About Zoetis

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Stock Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related stocks with our FREE daily email newsletter.